GITNUXREPORT 2026

Japan Pharmacy Industry Statistics

Japan's pharmacy industry is growing steadily through innovation while generic drug use rises.

Sarah Mitchell

Senior Researcher specializing in consumer behavior and market trends.

First published: Feb 13, 2026

Our Commitment to Accuracy

Rigorous fact-checking · Reputable sources · Regular updatesLearn more

Statistic 1

Japan pharma market projected to grow at 3.2% CAGR to 5.5 trillion JPY by 2028.

Statistic 2

Generic penetration expected to reach 90% by 2026 in Japan.

Statistic 3

Digital health integration in pharmacies to cover 80% by 2030.

Statistic 4

Biosimilars market forecasted to 800 billion JPY by 2027.

Statistic 5

Personalized medicine R&D investment to double to 500 billion JPY by 2028.

Statistic 6

AI-driven drug discovery to contribute 20% of new approvals by 2030.

Statistic 7

Pharmacy retail consolidation to reduce outlets to 45,000 by 2030.

Statistic 8

Regenerative medicine market to 1 trillion JPY by 2030 in Japan.

Statistic 9

E-prescription adoption to 100% by end of 2025.

Statistic 10

Oncology innovations to drive 12% CAGR to 1.5 trillion JPY by 2028.

Statistic 11

Japan's pharmaceutical market was valued at 4.8 trillion JPY in 2023, marking a 2.1% year-over-year growth driven by innovative therapies.

Statistic 12

The prescription drug segment accounted for 78% of total pharmaceutical sales in Japan during fiscal year 2022.

Statistic 13

Japan's over-the-counter (OTC) drug market size stood at 780 billion JPY in 2023.

Statistic 14

Generic drug penetration in Japan reached 82.5% of the volume in the generic-promotable market by March 2024.

Statistic 15

The biopharmaceutical market in Japan grew by 15.4% to 1.2 trillion JPY in 2023.

Statistic 16

Japan's pharmacy retail market had 55,000 outlets in 2023, down 1.2% from previous year.

Statistic 17

Total healthcare expenditure on pharmaceuticals in Japan was 11.5% of national health spending in 2022.

Statistic 18

The cell and gene therapy market in Japan expanded to 45 billion JPY in fiscal 2023.

Statistic 19

Japan's drugstore sales reached 14.2 trillion JPY in 2023, including non-pharma items.

Statistic 20

The hospital pharmacy segment supplied 42% of prescription drugs in Japan in 2022.

Statistic 21

Japan's pharma imports totaled 2.1 trillion JPY in 2023, mainly from Europe and US.

Statistic 22

Domestic pharma production in Japan was valued at 6.5 trillion JPY in fiscal 2023.

Statistic 23

The market share of top 10 pharma companies in Japan was 65% in 2023.

Statistic 24

Japan's per capita spending on prescription drugs was 92,000 JPY in 2022.

Statistic 25

The oncology drug market in Japan grew 8.7% to 850 billion JPY in 2023.

Statistic 26

Japan's pharmaceutical R&D expenditure reached 1.1 trillion JPY in 2022.

Statistic 27

The size of Japan's digital pharmacy market was 120 billion JPY in 2023.

Statistic 28

Pharmacy benefit reimbursement in Japan covered 98.5% of prescriptions in 2023.

Statistic 29

Japan's vaccine market volume increased by 25% to 300 billion JPY post-COVID in 2023.

Statistic 30

The rare disease drug market in Japan was 250 billion JPY in fiscal 2023.

Statistic 31

Japan's pharma wholesale market turnover was 7.8 trillion JPY in 2023.

Statistic 32

E-pharmacy sales grew 35% year-over-year to 150 billion JPY in 2023.

Statistic 33

The dermatology pharma segment in Japan reached 180 billion JPY in 2022.

Statistic 34

Japan's pharmacy chain stores numbered 24,500 in 2023, up 2.3%.

Statistic 35

Anti-infective drugs comprised 12% of Japan's pharma market in 2023.

Statistic 36

Japan's biosimilar market size hit 400 billion JPY in 2023.

Statistic 37

Central nervous system drugs sales were 650 billion JPY in Japan 2023.

Statistic 38

Japan's pharma export value was 1.05 trillion JPY in 2023.

Statistic 39

The immunology drug market in Japan grew to 550 billion JPY in 2023.

Statistic 40

Japan's independent pharmacies accounted for 45% of retail outlets in 2023.

Statistic 41

OTC sales for cold remedies hit 120 billion JPY in 2023.

Statistic 42

Drugstore footfall averaged 1.2 million daily across Japan 2023.

Statistic 43

Pain relief OTC products held 25% market share in 2023.

Statistic 44

Pharmacy chains captured 75% of OTC sales in Japan 2023.

Statistic 45

Vitamin supplements OTC sales grew 6% to 150 billion JPY 2023.

Statistic 46

Average OTC purchase value per visit was 1,500 JPY in 2023.

Statistic 47

Stomach medicine OTC dominated with 18% share in 2023.

Statistic 48

Rural pharmacies served 30% fewer customers than urban in 2023.

Statistic 49

Beauty health OTC category sales up 12% to 90 billion JPY 2023.

Statistic 50

Self-medication rate reached 45% of population in Japan 2023.

Statistic 51

Eye care OTC products sales 60 billion JPY in FY2023.

Statistic 52

24-hour pharmacies numbered 12,000 in Japan end-2023.

Statistic 53

Herbal medicine OTC sales stable at 110 billion JPY 2023.

Statistic 54

Pharmacist counseling rate for OTC was 65% in 2023 surveys.

Statistic 55

Oral care OTC market 40 billion JPY growth 5% in 2023.

Statistic 56

Elderly OTC buyers over 65 comprised 40% in 2023.

Statistic 57

Allergy OTC sales spiked 20% to 75 billion JPY 2023.

Statistic 58

Pharmacy loyalty programs covered 55 million members 2023.

Statistic 59

Non-pharma sales in drugstores 60% of total revenue 2023.

Statistic 60

Laxative OTC top seller with 50 billion JPY sales 2023.

Statistic 61

Mobile app users for pharmacy services 20 million in 2023.

Statistic 62

Women's health OTC grew 10% to 35 billion JPY 2023.

Statistic 63

Pharmacy delivery services reached 1 million orders monthly 2023.

Statistic 64

Sleep aid OTC sales 45 billion JPY amid stress rise 2023.

Statistic 65

Kids OTC products 30 billion JPY market in Japan 2023.

Statistic 66

Average prescription reimbursement price was 1,200 JPY per item in 2023.

Statistic 67

Number of prescriptions per capita in Japan was 12.5 annually in 2023.

Statistic 68

Generic substitution rate hit 85% for applicable drugs in FY2023.

Statistic 69

Top prescribed drug class was antihypertensives at 28% of total in 2023.

Statistic 70

Antibiotic prescription rate declined to 15% of total in Japan 2023.

Statistic 71

Chronic disease prescriptions accounted for 65% of total volume 2023.

Statistic 72

Opioid prescriptions increased 12% to 5 million in Japan FY2023.

Statistic 73

Statin prescriptions totaled 45 million units in Japan 2023.

Statistic 74

Proton pump inhibitor scripts rose 8% to 30 million in 2023.

Statistic 75

Antidiabetic prescriptions reached 25 million annually in Japan 2023.

Statistic 76

Oncology prescriptions grew 10% to 4.2 million in FY2023.

Statistic 77

Average prescription length was 45 days for chronic meds in 2023.

Statistic 78

Pediatric prescriptions dropped 5% to 120 million in Japan 2023.

Statistic 79

Antidepressant scripts increased 18% to 12 million in 2023.

Statistic 80

Vaccine prescriptions surged 30% post-pandemic to 80 million doses 2023.

Statistic 81

Dispensing fee per prescription averaged 850 JPY in FY2023.

Statistic 82

Polypharmacy rate over 5 drugs was 25% in elderly patients 2023.

Statistic 83

Biosimilar prescriptions tripled to 15 million units in 2023.

Statistic 84

Allergy drug prescriptions peaked at 18 million in spring 2023.

Statistic 85

Insulin prescriptions stable at 6.5 million in Japan 2023.

Statistic 86

Dementia med prescriptions up 22% to 3.8 million FY2023.

Statistic 87

70% of prescriptions issued electronically in Japan by 2023.

Statistic 88

Antihistamine scripts totaled 22 million units annually 2023.

Statistic 89

GLP-1 agonist prescriptions exploded 50% to 2.5 million 2023.

Statistic 90

Topical steroid prescriptions 16 million in dermatology 2023.

Statistic 91

Retail pharmacy dispensing rate 55% of total prescriptions 2023.

Statistic 92

Total prescription volume in Japan was 3.2 billion in fiscal 2023.

Statistic 93

Pharma sales revenue for Eisai Co. reached 800 billion JPY in FY2023.

Statistic 94

Takeda Pharmaceutical's Japan revenue was 1.2 trillion JPY in 2023.

Statistic 95

OTC sales revenue grew 4.2% to 820 billion JPY in Japan 2023.

Statistic 96

Astellas Pharma's domestic sales hit 650 billion JPY in FY2023.

Statistic 97

Daiichi Sankyo revenue from Japan market was 550 billion JPY in 2023.

Statistic 98

Generic drug sales revenue reached 1.8 trillion JPY in Japan 2023.

Statistic 99

Chugai Pharmaceutical's sales in Japan totaled 750 billion JPY FY2023.

Statistic 100

Pharmacy retail revenue per store averaged 250 million JPY in 2023.

Statistic 101

Ono Pharmaceutical revenue was 450 billion JPY domestically in 2023.

Statistic 102

Japan's top 20 pharma firms generated 70% of total industry revenue in 2023.

Statistic 103

Kyowa Kirin Japan sales reached 300 billion JPY in FY2023.

Statistic 104

Brand-name drug sales declined 3.5% to 2.9 trillion JPY in 2023.

Statistic 105

Shionogi & Co. revenue from Japan was 380 billion JPY in 2023.

Statistic 106

Online pharmacy revenue surged 40% to 180 billion JPY in 2023.

Statistic 107

Meiji Seika Pharma sales in Japan hit 220 billion JPY FY2023.

Statistic 108

Hospital drug procurement revenue was 3.1 trillion JPY in 2023.

Statistic 109

Sawai Pharmaceutical generic sales 950 billion JPY in Japan 2023.

Statistic 110

Nippon Shinyaku revenue domestically 180 billion JPY FY2023.

Statistic 111

Pharma wholesaler Medipal Holdings revenue 2.4 trillion JPY 2023.

Statistic 112

Towa Pharmaceutical sales 320 billion JPY in Japan 2023.

Statistic 113

Alcon Japan revenue from pharma products 150 billion JPY 2023.

Statistic 114

Pharmacy chain MatsuMotoKiyoshi sales 1.1 trillion JPY FY2023.

Statistic 115

Nichi-Iko Pharmaceutical generic revenue 280 billion JPY 2023.

Statistic 116

Welcia Holdings pharmacy revenue 1.8 trillion JPY in 2023.

Statistic 117

Cardiovascular drug sales revenue 750 billion JPY in Japan 2023.

Statistic 118

Sugi Holdings total revenue 1.5 trillion JPY FY2023.

Statistic 119

Diabetes drug sales 450 billion JPY in Japan market 2023.

Statistic 120

Kokando OTC revenue 50 billion JPY in Japan 2023.

Statistic 121

Tsuruha Holdings pharmacy sales 2.2 trillion JPY 2023.

Statistic 122

Antiviral drug sales peaked at 900 billion JPY in Japan 2023.

1/122

Sources

Trusted by 500+ publications

+497

From the explosive 50% surge in GLP-1 agonist prescriptions to a generics market commanding over 82% volume share, Japan’s pharmaceutical landscape is undergoing a profound transformation driven by innovation, demographic shifts, and evolving patient behaviors.

Key Takeaways

Japan's pharmaceutical market was valued at 4.8 trillion JPY in 2023, marking a 2.1% year-over-year growth driven by innovative therapies.
The prescription drug segment accounted for 78% of total pharmaceutical sales in Japan during fiscal year 2022.
Japan's over-the-counter (OTC) drug market size stood at 780 billion JPY in 2023.
Total prescription volume in Japan was 3.2 billion in fiscal 2023.
Pharma sales revenue for Eisai Co. reached 800 billion JPY in FY2023.
Takeda Pharmaceutical's Japan revenue was 1.2 trillion JPY in 2023.
Average prescription reimbursement price was 1,200 JPY per item in 2023.
Number of prescriptions per capita in Japan was 12.5 annually in 2023.
Generic substitution rate hit 85% for applicable drugs in FY2023.
OTC sales for cold remedies hit 120 billion JPY in 2023.
Drugstore footfall averaged 1.2 million daily across Japan 2023.
Pain relief OTC products held 25% market share in 2023.
Japan pharma market projected to grow at 3.2% CAGR to 5.5 trillion JPY by 2028.
Generic penetration expected to reach 90% by 2026 in Japan.
Digital health integration in pharmacies to cover 80% by 2030.

Japan's pharmacy industry is growing steadily through innovation while generic drug use rises.

Future Projections and Innovations

Japan pharma market projected to grow at 3.2% CAGR to 5.5 trillion JPY by 2028.
Generic penetration expected to reach 90% by 2026 in Japan.
Digital health integration in pharmacies to cover 80% by 2030.
Biosimilars market forecasted to 800 billion JPY by 2027.
Personalized medicine R&D investment to double to 500 billion JPY by 2028.
AI-driven drug discovery to contribute 20% of new approvals by 2030.
Pharmacy retail consolidation to reduce outlets to 45,000 by 2030.
Regenerative medicine market to 1 trillion JPY by 2030 in Japan.
E-prescription adoption to 100% by end of 2025.
Oncology innovations to drive 12% CAGR to 1.5 trillion JPY by 2028.

Future Projections and Innovations Interpretation

Japan's pharmacy sector is carefully modernizing its prescription, aiming for near-total generic efficiency and digital integration while ruthlessly consolidating its retail front, all to fuel a precision-engineered future where biosimilars, AI, and personalized cures like oncology and regenerative medicine become the high-margin growth engines powering a steady but significant market expansion.

Market Overview

Japan's pharmaceutical market was valued at 4.8 trillion JPY in 2023, marking a 2.1% year-over-year growth driven by innovative therapies.
The prescription drug segment accounted for 78% of total pharmaceutical sales in Japan during fiscal year 2022.
Japan's over-the-counter (OTC) drug market size stood at 780 billion JPY in 2023.
Generic drug penetration in Japan reached 82.5% of the volume in the generic-promotable market by March 2024.
The biopharmaceutical market in Japan grew by 15.4% to 1.2 trillion JPY in 2023.
Japan's pharmacy retail market had 55,000 outlets in 2023, down 1.2% from previous year.
Total healthcare expenditure on pharmaceuticals in Japan was 11.5% of national health spending in 2022.
The cell and gene therapy market in Japan expanded to 45 billion JPY in fiscal 2023.
Japan's drugstore sales reached 14.2 trillion JPY in 2023, including non-pharma items.
The hospital pharmacy segment supplied 42% of prescription drugs in Japan in 2022.
Japan's pharma imports totaled 2.1 trillion JPY in 2023, mainly from Europe and US.
Domestic pharma production in Japan was valued at 6.5 trillion JPY in fiscal 2023.
The market share of top 10 pharma companies in Japan was 65% in 2023.
Japan's per capita spending on prescription drugs was 92,000 JPY in 2022.
The oncology drug market in Japan grew 8.7% to 850 billion JPY in 2023.
Japan's pharmaceutical R&D expenditure reached 1.1 trillion JPY in 2022.
The size of Japan's digital pharmacy market was 120 billion JPY in 2023.
Pharmacy benefit reimbursement in Japan covered 98.5% of prescriptions in 2023.
Japan's vaccine market volume increased by 25% to 300 billion JPY post-COVID in 2023.
The rare disease drug market in Japan was 250 billion JPY in fiscal 2023.
Japan's pharma wholesale market turnover was 7.8 trillion JPY in 2023.
E-pharmacy sales grew 35% year-over-year to 150 billion JPY in 2023.
The dermatology pharma segment in Japan reached 180 billion JPY in 2022.
Japan's pharmacy chain stores numbered 24,500 in 2023, up 2.3%.
Anti-infective drugs comprised 12% of Japan's pharma market in 2023.
Japan's biosimilar market size hit 400 billion JPY in 2023.
Central nervous system drugs sales were 650 billion JPY in Japan 2023.
Japan's pharma export value was 1.05 trillion JPY in 2023.
The immunology drug market in Japan grew to 550 billion JPY in 2023.
Japan's independent pharmacies accounted for 45% of retail outlets in 2023.

Market Overview Interpretation

Amidst a sea of remarkably affordable generics, Japan's pharmaceutical industry is paradoxically sailing forward on the expensive winds of biotech innovation, with a massive prescription-driven market meticulously supplied through a slightly shrinking yet still dense network of pharmacies.

OTC and Retail Pharmacy

OTC sales for cold remedies hit 120 billion JPY in 2023.
Drugstore footfall averaged 1.2 million daily across Japan 2023.
Pain relief OTC products held 25% market share in 2023.
Pharmacy chains captured 75% of OTC sales in Japan 2023.
Vitamin supplements OTC sales grew 6% to 150 billion JPY 2023.
Average OTC purchase value per visit was 1,500 JPY in 2023.
Stomach medicine OTC dominated with 18% share in 2023.
Rural pharmacies served 30% fewer customers than urban in 2023.
Beauty health OTC category sales up 12% to 90 billion JPY 2023.
Self-medication rate reached 45% of population in Japan 2023.
Eye care OTC products sales 60 billion JPY in FY2023.
24-hour pharmacies numbered 12,000 in Japan end-2023.
Herbal medicine OTC sales stable at 110 billion JPY 2023.
Pharmacist counseling rate for OTC was 65% in 2023 surveys.
Oral care OTC market 40 billion JPY growth 5% in 2023.
Elderly OTC buyers over 65 comprised 40% in 2023.
Allergy OTC sales spiked 20% to 75 billion JPY 2023.
Pharmacy loyalty programs covered 55 million members 2023.
Non-pharma sales in drugstores 60% of total revenue 2023.
Laxative OTC top seller with 50 billion JPY sales 2023.
Mobile app users for pharmacy services 20 million in 2023.
Women's health OTC grew 10% to 35 billion JPY 2023.
Pharmacy delivery services reached 1 million orders monthly 2023.
Sleep aid OTC sales 45 billion JPY amid stress rise 2023.
Kids OTC products 30 billion JPY market in Japan 2023.

OTC and Retail Pharmacy Interpretation

Despite the Japanese public’s resolute self-medication, with nearly half the population reaching for the OTC shelf and pain relief leading the charge, the nation’s pharmacies shrewdly ensure you’ll also walk out with vitamins, a beauty product, and a loyalty card, all after a reassuring chat with a pharmacist who knows your 1,500 yen purchase helps keep the lights on in a 24-hour world where even rural access is a sore point.

Prescription Trends

Average prescription reimbursement price was 1,200 JPY per item in 2023.
Number of prescriptions per capita in Japan was 12.5 annually in 2023.
Generic substitution rate hit 85% for applicable drugs in FY2023.
Top prescribed drug class was antihypertensives at 28% of total in 2023.
Antibiotic prescription rate declined to 15% of total in Japan 2023.
Chronic disease prescriptions accounted for 65% of total volume 2023.
Opioid prescriptions increased 12% to 5 million in Japan FY2023.
Statin prescriptions totaled 45 million units in Japan 2023.
Proton pump inhibitor scripts rose 8% to 30 million in 2023.
Antidiabetic prescriptions reached 25 million annually in Japan 2023.
Oncology prescriptions grew 10% to 4.2 million in FY2023.
Average prescription length was 45 days for chronic meds in 2023.
Pediatric prescriptions dropped 5% to 120 million in Japan 2023.
Antidepressant scripts increased 18% to 12 million in 2023.
Vaccine prescriptions surged 30% post-pandemic to 80 million doses 2023.
Dispensing fee per prescription averaged 850 JPY in FY2023.
Polypharmacy rate over 5 drugs was 25% in elderly patients 2023.
Biosimilar prescriptions tripled to 15 million units in 2023.
Allergy drug prescriptions peaked at 18 million in spring 2023.
Insulin prescriptions stable at 6.5 million in Japan 2023.
Dementia med prescriptions up 22% to 3.8 million FY2023.
70% of prescriptions issued electronically in Japan by 2023.
Antihistamine scripts totaled 22 million units annually 2023.
GLP-1 agonist prescriptions exploded 50% to 2.5 million 2023.
Topical steroid prescriptions 16 million in dermatology 2023.
Retail pharmacy dispensing rate 55% of total prescriptions 2023.

Prescription Trends Interpretation

Japan’s pharmacy landscape paints a picture of a nation expertly managing chronic ailments with generics and long prescriptions, while cautiously navigating new demands for weight loss drugs and opioids, all under the watchful eye of a reimbursement system that pays less for each pill but is flooded with them.

Sales and Revenue

Total prescription volume in Japan was 3.2 billion in fiscal 2023.
Pharma sales revenue for Eisai Co. reached 800 billion JPY in FY2023.
Takeda Pharmaceutical's Japan revenue was 1.2 trillion JPY in 2023.
OTC sales revenue grew 4.2% to 820 billion JPY in Japan 2023.
Astellas Pharma's domestic sales hit 650 billion JPY in FY2023.
Daiichi Sankyo revenue from Japan market was 550 billion JPY in 2023.
Generic drug sales revenue reached 1.8 trillion JPY in Japan 2023.
Chugai Pharmaceutical's sales in Japan totaled 750 billion JPY FY2023.
Pharmacy retail revenue per store averaged 250 million JPY in 2023.
Ono Pharmaceutical revenue was 450 billion JPY domestically in 2023.
Japan's top 20 pharma firms generated 70% of total industry revenue in 2023.
Kyowa Kirin Japan sales reached 300 billion JPY in FY2023.
Brand-name drug sales declined 3.5% to 2.9 trillion JPY in 2023.
Shionogi & Co. revenue from Japan was 380 billion JPY in 2023.
Online pharmacy revenue surged 40% to 180 billion JPY in 2023.
Meiji Seika Pharma sales in Japan hit 220 billion JPY FY2023.
Hospital drug procurement revenue was 3.1 trillion JPY in 2023.
Sawai Pharmaceutical generic sales 950 billion JPY in Japan 2023.
Nippon Shinyaku revenue domestically 180 billion JPY FY2023.
Pharma wholesaler Medipal Holdings revenue 2.4 trillion JPY 2023.
Towa Pharmaceutical sales 320 billion JPY in Japan 2023.
Alcon Japan revenue from pharma products 150 billion JPY 2023.
Pharmacy chain MatsuMotoKiyoshi sales 1.1 trillion JPY FY2023.
Nichi-Iko Pharmaceutical generic revenue 280 billion JPY 2023.
Welcia Holdings pharmacy revenue 1.8 trillion JPY in 2023.
Cardiovascular drug sales revenue 750 billion JPY in Japan 2023.
Sugi Holdings total revenue 1.5 trillion JPY FY2023.
Diabetes drug sales 450 billion JPY in Japan market 2023.
Kokando OTC revenue 50 billion JPY in Japan 2023.
Tsuruha Holdings pharmacy sales 2.2 trillion JPY 2023.
Antiviral drug sales peaked at 900 billion JPY in Japan 2023.

Sales and Revenue Interpretation

Japan's pharmacies are dispensing staggering sums, proving that the nation's health is a booming, generics-fueled, and increasingly online marketplace where even a common cold seems to require a corporate merger to finance.

Sources & References

Logos provided by Logo.dev